MESO vs CYTK

For growth investors, Cytokinetics, Incorporated (CYTK) is the stronger pick with 376.

6% revenue growth year-over-year, versus 191. 4% for Mesoblast Limited (MESO). Analysts rate Mesoblast Limited (MESO) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Cytokinetics, Incorporated (CYTK) delivered a total return of +206.

6%, compared to +6. 0% for Mesoblast Limited (MESO). Over 10 years, the gap is even starker: CYTK returned +817. 2% versus MESO's -2. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Cytokinetics, Incorporated (CYTK) is the lower-risk stock at 0.

66β versus Mesoblast Limited's 1. 70β — meaning MESO is approximately 155% more volatile than CYTK relative to the S&P 500.

By revenue growth (latest reported year), Cytokinetics, Incorporated (CYTK) is pulling ahead at 376.

6% versus 191. 4% for Mesoblast Limited (MESO). On earnings-per-share growth, the picture is similar: Mesoblast Limited grew EPS 5. 6% year-over-year, compared to -24. 3% for Cytokinetics, Incorporated. Over a 3-year CAGR, MESO leads at 19. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Mesoblast Limited (MESO) is the more profitable company, earning -593.

9% net margin versus -891. 6% for Cytokinetics, Incorporated — meaning it keeps -593. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MESO leads at -363. 1% versus -695. 4% for CYTK. At the gross margin level — before operating expenses — CYTK leads at 88. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Cytokinetics, Incorporated (CYTK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

66), +817. 2% 10Y return). Mesoblast Limited (MESO) carries a higher beta of 1. 70 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CYTK: +817. 2%, MESO: -2. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.